#151097

Anti-EGFR [F4]

Cat. #151097

Anti-EGFR [F4]

Cat. #: 151097

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-5 days

Target: Epidermal Growth Factor Receptor (EGFR, Her1)

Class: Monoclonal

Application: ELISA ; FACS ; IHC ; IP ; RIA

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Joyce Taylor-Papadimitriou

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-EGFR [F4]
  • Research fields: Cancer;Cell signaling and signal transduction
  • Clone: F4
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; FACS ; IHC ; IP ; RIA
  • Description: The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). Dysregulation of EGFR signaling as a consequence of overexpression, amplification and mutation of the EGFR gene occurs frequently in several types of cancers and many become dependent on EGFR signaling to maintain their malignant phenotypes.
  • Immunogen: Synthetic peptide (residues 985 to 996 of human EGFR) coupled to keyhole limpet hemocyanin.
  • Isotype: IgG1 kappa
  • Myeloma used: P3/NS1/1-Ag4.1

Target Details

  • Target: Epidermal Growth Factor Receptor (EGFR, Her1)
  • Target background: The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). Dysregulation of EGFR signaling as a consequence of overexpression, amplification and mutation of the EGFR gene occurs frequently in several types of cancers and many become dependent on EGFR signaling to maintain their malignant phenotypes.

Applications

  • Application: ELISA ; FACS ; IHC ; IP ; RIA

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: '-15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Jaganathan et al. 2011. PLoS One. 6(5):e19605. PMID: 21573184.
  • Gibson et al. 2009. PLoS One. 4(9):e7222. PMID: 19787046.
  • Berger et al. 1987. J Pathol. 152(4):297-307. PMID: 3668732.
  • Gullick et al. 1986. Cancer Res. 46(1):285-92. PMID: 2998607.